1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Clinical information of the enrolled patients
Variable True Progression (n = 15) Pseudoprogression (n = 22) P Value^{^a}
Age, yr (mean ± SD) 59.6 ± 11.9 56.7 ± 13.7 .61
Gender .12
    Male 9 (60.0%) 17 (77.3%) 
    Female 6 (40.0%) 5 (22.7%) 
Surgery .24
    Biopsy 4 (26.7%) 2 (9.1%) 
    Subtotal 6 (40.0%) 9 (40.9%) 
    Total 5 (33.3%) 11 (50.0%) 
Time interval of end of TMZ-chemoradiation to DCE MRI, d (mean ± SD [range]) 27.0 ± 7.3 [15–44] 28.7 ± 6.0 [17–44] .39
End of adjuvant TMZ chemotherapy to follow-up MRI, d (mean ± SD [range]) 31.2 ± 10.6 [20–53]^{^b} 26.2 ± 8.7 [16–54] .46
Initial operation to the last follow-up, d (mean ± SD [range]) 391.4 ± 156.3 [224–716] 657.3374.7 [274–1774] .002
↵a P values are from either Student t test or the χ² test, as appropriate, for all variables.
↵b Four patients who underwent pathologic confirmation (n = 2) or developed obvious clinical deterioration before the termination of adjuvant TMZ chemotherapy (n = 2) were excluded for this parameter.